- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Biochemistry Research International
Volume 2012 (2012), Article ID 518437, 9 pages
Regulator of G-Protein Signaling 5 Reduces HeyA8 Ovarian Cancer Cell Proliferation and Extends Survival in a Murine Tumor Model
1Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, Pharmacy South Building, The University of Georgia, Athens, GA 30602, USA
2The University of Georgia Medical Partnership, 279 Williams Street, Athens, GA 30602, USA
Received 6 April 2012; Accepted 19 April 2012
Academic Editor: Rolf J. Craven
Copyright © 2012 Molly K. Altman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. Zhou, K. Moroi, M. Nishiyama et al., “Characterization of RGS5 in regulation of G protein-coupled receptor signaling,” Life Sciences, vol. 68, no. 13, pp. 1457–1469, 2001.
- C. Chen, B. Zheng, J. Han, and S. C. Lin, “Characterization of a novel mammalian RGS protein that binds to Gα proteins and inhibits pheromone signaling in yeast,” The Journal of Biological Chemistry, vol. 272, no. 13, pp. 8679–8685, 1997.
- N. Seki, S. Sugano, Y. Suzuki et al., “Isolation, tissue expression, and chromosomal assignment of human RGS5, a novel G-protein signaling regulator gene,” Journal of Human Genetics, vol. 43, no. 3, pp. 202–205, 1998.
- B. Xiao, Y. Zhang, W. Q. Niu, P. J. Gao, and D. L. Zhu, “Haplotype-based association of regulator of G-protein signaling 5 gene polymorphisms with essential hypertension and metabolic parameters in Chinese,” Clinical Chemistry and Laboratory Medicine, vol. 47, no. 12, pp. 1483–1488, 2009.
- Y. P. C. Chang, X. Liu, J. D. O. Kim et al., “Multiple genes for essential-hypertension susceptibility on chromosome 1q,” American Journal of Human Genetics, vol. 80, no. 2, pp. 253–264, 2007.
- M. U. Faruque, G. Chen, A. Doumatey, et al., “Association of ATP1B1, RGS5 and SELE polymorphisms with hypertension and blood pressure in African-Americans,” Journal of Hypertension, vol. 29, no. 10, pp. 1906–1912, 2011.
- H. Cho, C. Park, I. Y. Hwang et al., “Rgs5 targeting leads to chronic low blood pressure and a lean body habitus,” Molecular and Cellular Biology, vol. 28, no. 8, pp. 2590–2597, 2008.
- D. B. Campbell, L. A. Lange, T. Skelly, J. Lieberman, P. Levitt, and P. F. Sullivan, “Association of RGS2 and RGS5 variants with schizophrenia symptom severity,” Schizophrenia Research, vol. 101, no. 1–3, pp. 67–75, 2008.
- E. N. Smith, C. S. Bloss, J. A. Badner et al., “Genome-wide association study of bipolar disorder in European American and African American individuals,” Molecular Psychiatry, vol. 14, no. 8, pp. 755–763, 2009.
- C. Bondjers, M. Kalén, M. Hellström et al., “Transcription profiling of platelet-derived growth factor-B-deficient mouse embryos identifies RGS5 as a novel marker for pericytes and vascular smooth muscle cells,” American Journal of Pathology, vol. 162, no. 3, pp. 721–729, 2003.
- M. Berger, G. Bergers, B. Arnold, G. J. Hammerling, and R. Ganss, “Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization,” Blood, vol. 105, no. 3, pp. 1094–1101, 2005.
- T. S. Mitchell, J. Bradley, G. S. Robinson, D. T. Shima, and Y. S. Ng, “RGS5 expression is a quantitative measure of pericyte coverage of blood vessels,” Angiogenesis, vol. 11, no. 2, pp. 141–151, 2008.
- M. Gerlinger, A. J. Rowan, S. Horswell, et al., “Intratumor heterogeneity and branched evolution revealed by multiregion sequencing,” The New England Journal of Medicine, vol. 366, pp. 883–892, 2012.
- A. Silini, C. Ghilardi, S. Figini, et al., “Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment,” Cellular and Molecular Life Sciences, vol. 69, no. 7, pp. 1167–1178, 2012.
- I. Papandreou, R. A. Cairns, L. Fontana, A. L. Lim, and N. C. Denko, “HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption,” Cell Metabolism, vol. 3, no. 3, pp. 187–197, 2006.
- O. Warburg, “On respiratory impairment in cancer cells,” Science, vol. 124, no. 3215, pp. 269–270, 1956.
- Y. Jin, X. An, Z. Ye, B. Cully, J. Wu, and J. Li, “RGS5, a hypoxia-inducible apoptotic stimulator in endothelial cells,” The Journal of Biological Chemistry, vol. 284, no. 35, pp. 23436–23443, 2009.
- R. A. Weinberg, Ed., The Biology of Cancer, Garland Science, Taylor & Francis Group, New York, NY, USA, 2007.
- S. M. Weis and D. A. Cheresh, “Pathophysiological consequences of VEGF-induced vascular permeability,” Nature, vol. 437, no. 7058, pp. 497–504, 2005.
- J. Hamzah, M. Jugold, F. Kiessling et al., “Vascular normalization in Rgs5-deficient tumours promotes immune destruction,” Nature, vol. 453, no. 7193, pp. 410–414, 2008.
- M. Manzur, J. Hamzah, and R. Ganss, “Modulation of the “blood-tumor” barrier improves immunotherapy,” Cell Cycle, vol. 7, no. 16, pp. 2452–2455, 2008.
- M. Manzur, J. Hamzah, and R. Ganss, “Modulation of G protein signaling normalizes tumor vessels,” Cancer Research, vol. 69, no. 2, pp. 396–399, 2009.
- S. B. Hooks, P. Callihan, M. K. Altman, J. H. Hurst, M. W. Ali, and M. M. Murph, “Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells,” Molecular Cancer, vol. 9, article 289, 2010.
- W. Jia, J. O. Eneh, S. Ratnaparkhe, M. K. Altman, and M. M. Murph, “MicroRNA-30c-2* expressed in ovarian cancer cells suppresses growth factor-induced cellular proliferation and downregulates the oncogene BCL9,” Molecular Cancer Research, vol. 9, pp. 1732–1745, 2011.
- G. Sorensen, K. Emblem, P. Polaskova, et al., “Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion,” Cancer Research, vol. 72, no. 2, pp. 402–407, 2012.
- O. Keunen, M. Johansson, A. Oudin et al., “Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 9, pp. 3749–3754, 2011.
- I. Genentech, “U.S. BL 125085 Supplement: Bevacizumab,” in South San Francisco, I. Genentech, Ed., pp. 1–23, 2011.
- D. B. Jackson and A. K. Sood, “Personalized cancer medicine—advances and socio-economic challenges,” Nature Reviews Clinical Oncology, vol. 8, pp. 735–741, 2011.